Mannkind Corp (MNKD)

$4.25 +0.03 (0.71%)
Market Cap 1.30B
Revenue (ttm) 348.97M
Net Income (ttm) 5.86M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 1.68%
Debt to Equity Ratio -7.13
Volume 6,892,600
Avg Vol 6,144,178
Day's Range N/A - N/A
Shares Out 308.95M
Stochastic %K 62%
Beta 1.09
Analysts Strong Sell
Price Target $7.59

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve glycemic control in adults with diabetes; and the V-Go wearable insulin delivery device, which provi...

Industry: Biotechnology
Sector: Healthcare
Phone: 818 661 5000
Address:
1 Casper Street, Danbury, United States
Yasherp
Yasherp Jul. 9 at 1:43 PM
$MNKD More than half year ago Afrezza approved in India and shiped to CIPLA end of 2025. How CIPLA is doing after half an year? The afrezza revenue will tear the roof after half an year? Or is it another BRAZIL?
1 · Reply
JustAnotherAffizle
JustAnotherAffizle Jul. 9 at 1:42 PM
$MNKD
0 · Reply
JustAnotherAffizle
JustAnotherAffizle Jul. 9 at 1:41 PM
$MNKD LOLZ!
0 · Reply
grampslol
grampslol Jul. 9 at 1:00 PM
$MNKD
0 · Reply
clan
clan Jul. 9 at 12:58 PM
$MNKD $UTHR I am the undisupted world champion heavyweight grand master Troll Triggerer.🏆 I live rent-free in AffizzledGrampspoo's twisted head.🧌
1 · Reply
grampslol
grampslol Jul. 9 at 12:43 PM
poor $MNKD pumper @clan ... smh ... delusional cultist chumping the gullible about nadaburger furoscizzle and it's ability to get the afizzle company out of pennyworld... a sad 🤡 ... #pumperslie $PFE $BX $JNJ
0 · Reply
ghcolleen88
ghcolleen88 Jul. 9 at 12:39 PM
$MNKD
0 · Reply
clan
clan Jul. 9 at 12:36 PM
$MNKD $SPY $$QQQ 🚨 Only 11 trading days until a new, very needed, FDA product approval. ❤️ #furoscix #mannkind 🤑
0 · Reply
grampslol
grampslol Jul. 9 at 12:34 PM
$MNKD thursday morning script review afrezza dpi inhaled prandial insulin approved in 2014 ... weekly scripts ending 6/26/2026 new 333 refills 426 ... a pharmaceutical flop of epic proportions #afizzle #pennylandforever
0 · Reply
clan
clan Jul. 9 at 12:29 PM
$MNKD $JNJ $PFE $BX Mannkind's revenue growth projections for its upcoming FDA-approved Furoscix Ready•Flow Autoinjector have evolved from analysts' conservative projections originally derived last year during scPharma market valuations being made. #milestones #buyout #undervalued Up and to the right.
0 · Reply
Latest News on MNKD
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Jun 23, 2026, 9:00 AM EDT - 16 days ago

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Jun 5, 2026, 7:35 PM EDT - 4 weeks ago

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

MannKind Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 9:20 AM EDT - 5 weeks ago

MannKind Transcript: Jefferies Global Healthcare Conference 2026

MannKind announces milestones in development of nintedanib DPI for IPF

2026-06-03T10:15:31.000Z - 5 weeks ago

MannKind announces milestones in development of nintedanib DPI for IPF

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

Jun 3, 2026, 6:05 AM EDT - 5 weeks ago

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

MannKind price target raised to $11 from $10 at Wells Fargo

2026-06-01T01:10:05.000Z - 5 weeks ago

MannKind price target raised to $11 from $10 at Wells Fargo

MannKind Transcript: FDA announcement

May 29, 2026, 4:30 PM EDT - 5 weeks ago

MannKind Transcript: FDA announcement

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

May 29, 2026, 2:00 PM EDT - 5 weeks ago

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

US FDA approves MannKind's inhaled insulin for children

May 29, 2026, 12:44 PM EDT - 5 weeks ago

US FDA approves MannKind's inhaled insulin for children

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

2026-05-29T16:35:11.000Z - 5 weeks ago

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

May 29, 2026, 12:30 PM EDT - 5 weeks ago

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026, 4:00 PM EDT - 6 weeks ago

MannKind to Present at Jefferies Global Healthcare Conference

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

May 27, 2026, 9:05 AM EDT - 6 weeks ago

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

MannKind Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 7 weeks ago

MannKind Transcript: AGM 2026

MannKind price target lowered to $7 from $8 at Mizuho

2026-05-07T15:49:43.000Z - 2 months ago

MannKind price target lowered to $7 from $8 at Mizuho

MannKind price target raised to $10 from $8 at H.C. Wainwright

2026-05-07T11:37:11.000Z - 2 months ago

MannKind price target raised to $10 from $8 at H.C. Wainwright

MannKind price target raised to $10 from $8 at Wells Fargo

2026-05-07T10:51:50.000Z - 2 months ago

MannKind price target raised to $10 from $8 at Wells Fargo

MannKind reports Q1 EPS (2c), consensus 1c

2026-05-07T01:17:30.000Z - 2 months ago

MannKind reports Q1 EPS (2c), consensus 1c

MannKind Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

MannKind Earnings Call Transcript: Q1 2026

MannKind Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

MannKind Earnings release: Q1 2026

MannKind Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

MannKind Quarterly report: Q1 2026

MannKind Slides: Q1 2026

May 6, 2026, 4:30 PM EDT - 2 months ago

MannKind Slides: Q1 2026

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

May 6, 2026, 4:01 PM EDT - 2 months ago

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

May 6, 2026, 6:30 AM EDT - 2 months ago

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 29, 2026, 4:01 PM EDT - 2 months ago

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

MannKind price target lowered to $8 from $10 at Mizuho

2026-04-13T14:45:40.000Z - 3 months ago

MannKind price target lowered to $8 from $10 at Mizuho

MannKind price target lowered to $6 from $7 at Truist

2026-04-08T12:35:39.000Z - 3 months ago

MannKind price target lowered to $6 from $7 at Truist

Theravance Biopharma price target raised to $17 from $14 at B. Riley

2026-04-07T12:31:26.000Z - 3 months ago

Theravance Biopharma price target raised to $17 from $14 at B. Riley

TBPH

MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

MannKind Proxy statement: Proxy filing

MannKind Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

MannKind Proxy statement: Proxy filing

MannKind Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 11, 2026, 1:00 PM EDT - 4 months ago

MannKind Transcript: Barclays 28th Annual Global Healthcare Conference

MannKind Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 3:40 PM EDT - 4 months ago

MannKind Transcript: Leerink Global Healthcare Conference 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

Mar 9, 2026, 9:05 AM EDT - 4 months ago

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

MannKind Announces Settlement of Convertible Senior Notes

Mar 5, 2026, 4:30 PM EST - 4 months ago

MannKind Announces Settlement of Convertible Senior Notes

MannKind price target lowered to $8 from $10 at Wedbush

2026-03-05T14:03:29.000Z - 4 months ago

MannKind price target lowered to $8 from $10 at Wedbush

UTHR

MannKind to Participate in Upcoming Investor Conferences

Mar 4, 2026, 9:00 AM EST - 4 months ago

MannKind to Participate in Upcoming Investor Conferences

Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink

2026-02-27T18:27:37.000Z - 4 months ago

Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink

IBB SLNO XBI XLV

MannKind price target lowered to $7 from $8 at Wells Fargo

2026-02-27T12:57:54.000Z - 4 months ago

MannKind price target lowered to $7 from $8 at Wells Fargo

MannKind price target lowered to $8 from $11 at H.C. Wainwright

2026-02-27T12:11:17.000Z - 4 months ago

MannKind price target lowered to $8 from $11 at H.C. Wainwright

MannKind downgraded to Sector Perform from Outperform at RBC Capital

2026-02-27T10:30:32.000Z - 4 months ago

MannKind downgraded to Sector Perform from Outperform at RBC Capital

UTHR

MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 11:20 AM EST - 4 months ago

MannKind Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind Earnings Call Transcript: Q4 2025

Feb 26, 2026, 9:00 AM EST - 4 months ago

MannKind Earnings Call Transcript: Q4 2025

MannKind Annual report: Q4 2025

Feb 26, 2026, 9:00 AM EST - 4 months ago

MannKind Annual report: Q4 2025

MannKind Earnings release: Q4 2025

Feb 26, 2026, 9:00 AM EST - 4 months ago

MannKind Earnings release: Q4 2025

MannKind Slides: Q4 2025

Feb 26, 2026, 9:00 AM EST - 4 months ago

MannKind Slides: Q4 2025

MannKind reports Q4 EPS (5c) vs 3c last year

2026-02-26T13:23:42.000Z - 4 months ago

MannKind reports Q4 EPS (5c) vs 3c last year

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 26, 2026, 8:00 AM EST - 4 months ago

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

2026-02-25T19:35:40.000Z - 4 months ago

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

UTHR

Leerink sees MannKind selloff as ‘overreaction’ to headline news

2026-02-25T18:20:50.000Z - 4 months ago

Leerink sees MannKind selloff as ‘overreaction’ to headline news

UTHR

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

2026-02-25T16:55:34.000Z - 4 months ago

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

UTHR

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 19, 2026, 9:00 AM EST - 5 months ago

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Feb 18, 2026, 9:00 AM EST - 5 months ago

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Feb 9, 2026, 6:05 AM EST - 5 months ago

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Jan 26, 2026, 6:05 AM EST - 5 months ago

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Jan 12, 2026, 3:57 PM EST - 6 months ago

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

AAPL DT GLD ITRN NVDA OMC UTHR

MannKind Slides: Corporate presentation

Jan 10, 2026, 7:00 AM EST - 6 months ago

MannKind Slides: Corporate presentation

MannKind Provides Business Updates and 2026 Growth Drivers

Jan 8, 2026, 8:05 AM EST - 6 months ago

MannKind Provides Business Updates and 2026 Growth Drivers

MannKind Shares FUROSCIX® Business Updates

Dec 23, 2025, 8:05 AM EST - 7 months ago

MannKind Shares FUROSCIX® Business Updates

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

Dec 1, 2025, 8:05 AM EST - 7 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease

MannKind Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 6:30 AM EST - 8 months ago

MannKind Transcript: Jefferies London Healthcare Conference 2025

MannKind to Present at the Jefferies Global Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 8 months ago

MannKind to Present at the Jefferies Global Healthcare Conference

MannKind Transcript: Study Update

Nov 10, 2025, 9:00 AM EST - 8 months ago

MannKind Transcript: Study Update

MannKind Press release: Study Update

Nov 10, 2025, 9:00 AM EST - 8 months ago

MannKind Press release: Study Update

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

Nov 10, 2025, 8:00 AM EST - 8 months ago

MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

Nov 6, 2025, 9:00 AM EST - 8 months ago

MannKind Commemorates Alfred E. Mann's 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes

MannKind Earnings Call Transcript: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

MannKind Earnings Call Transcript: Q3 2025

MannKind Quarterly report: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

MannKind Quarterly report: Q3 2025

MannKind Earnings release: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

MannKind Earnings release: Q3 2025

MannKind Slides: Q3 2025

Nov 5, 2025, 9:00 AM EST - 8 months ago

MannKind Slides: Q3 2025

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:00 AM EST - 8 months ago

MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

Oct 29, 2025, 4:05 PM EDT - 9 months ago

MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

Oct 13, 2025, 8:05 AM EDT - 9 months ago

MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

Oct 7, 2025, 9:02 AM EDT - 9 months ago

MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

Sep 29, 2025, 6:05 AM EDT - 10 months ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

Sep 16, 2025, 12:17 PM EDT - 10 months ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

MannKind Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 10, 2025, 2:35 PM EDT - 10 months ago

MannKind Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

MannKind Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:30 AM EDT - 10 months ago

MannKind Transcript: H.C. Wainwright 27th Annual Global Investment Conference

MannKind Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 9:45 AM EDT - 11 months ago

MannKind Transcript: Cantor Global Healthcare Conference 2025

MannKind Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 4:30 PM EDT - 11 months ago

MannKind Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 4:05 PM EDT - 11 months ago

MannKind to Present at Upcoming Investor Conferences

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 27, 2025, 8:05 AM EDT - 11 months ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

MannKind Transcript: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 11 months ago

MannKind Transcript: M&A Announcement

MannKind Press release: M&A Announcement

Aug 25, 2025, 8:30 AM EDT - 11 months ago

MannKind Press release: M&A Announcement

MannKind Earnings Call Transcript: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q2 2025

MannKind Quarterly report: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Quarterly report: Q2 2025

MannKind Earnings release: Q2 2025

Aug 6, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings release: Q2 2025

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:10 AM EDT - 1 year ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Aug 6, 2025, 7:05 AM EDT - 1 year ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

MannKind Slides: Corporate Presentation

Aug 6, 2025, 7:00 AM EDT - 1 year ago

MannKind Slides: Corporate Presentation

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jul 30, 2025, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

Jun 9, 2025, 4:05 PM EDT - 1 year ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

MannKind Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

MannKind Transcript: Jefferies Global Healthcare Conference 2025

MannKind Slides: FY 2025

Jun 5, 2025, 2:35 PM EDT - 1 year ago

MannKind Slides: FY 2025

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 9:15 AM EDT - 1 year ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

MannKind Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 8:00 AM EDT - 1 year ago

MannKind Transcript: RBC Capital Markets Global Healthcare Conference 2025

MannKind Earnings Call Transcript: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings Call Transcript: Q1 2025

MannKind Quarterly report: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Quarterly report: Q1 2025

MannKind Earnings release: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

MannKind Earnings release: Q1 2025

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025, 8:05 AM EDT - 1 year ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

May 1, 2025, 4:05 PM EDT - 1 year ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Apr 7, 2025, 12:30 PM EDT - 1 year ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing

MannKind Proxy statement: Proxy Filing

Apr 1, 2025, 8:00 AM EDT - 1 year ago

MannKind Proxy statement: Proxy Filing

MannKind Transcript: Barclays 26th Annual Global Healthcare Conference

Mar 12, 2025, 1:30 PM EDT - 1 year ago

MannKind Transcript: Barclays 26th Annual Global Healthcare Conference

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Mar 10, 2025, 6:05 AM EDT - 1 year ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

MannKind Earnings Call Transcript: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q4 2024

MannKind Annual report: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Annual report: Q4 2024

MannKind Earnings release: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Earnings release: Q4 2024

MannKind Slides: Q4 2024

Feb 26, 2025, 4:30 PM EST - 1 year ago

MannKind Slides: Q4 2024

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 19, 2025, 4:05 PM EST - 1 year ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

MannKind Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 11:20 AM EST - 1 year ago

MannKind Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

MannKind Expands Executive Leadership Team

Jan 6, 2025, 4:30 PM EST - 1 year ago

MannKind Expands Executive Leadership Team

MannKind Transcript: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

MannKind Transcript: Study Result

MannKind Press release: Study Result

Dec 16, 2024, 8:30 AM EST - 1 year ago

MannKind Press release: Study Result

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 16, 2024, 6:05 AM EST - 1 year ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Dec 11, 2024, 6:00 AM EST - 1 year ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MannKind Transcript: UBS Global Healthcare Conference 2024

Nov 12, 2024, 1:15 PM EST - 1 year ago

MannKind Transcript: UBS Global Healthcare Conference 2024

MannKind Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Earnings Call Transcript: Q3 2024

MannKind Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Quarterly report: Q3 2024

MannKind Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

MannKind Earnings release: Q3 2024

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 7, 2024, 4:02 PM EST - 1 year ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MannKind to Present at 2024 UBS Healthcare Conference

Nov 5, 2024, 4:15 PM EST - 1 year ago

MannKind to Present at 2024 UBS Healthcare Conference

Yasherp
Yasherp Jul. 9 at 1:43 PM
$MNKD More than half year ago Afrezza approved in India and shiped to CIPLA end of 2025. How CIPLA is doing after half an year? The afrezza revenue will tear the roof after half an year? Or is it another BRAZIL?
1 · Reply
JustAnotherAffizle
JustAnotherAffizle Jul. 9 at 1:42 PM
$MNKD
0 · Reply
JustAnotherAffizle
JustAnotherAffizle Jul. 9 at 1:41 PM
$MNKD LOLZ!
0 · Reply
grampslol
grampslol Jul. 9 at 1:00 PM
$MNKD
0 · Reply
clan
clan Jul. 9 at 12:58 PM
$MNKD $UTHR I am the undisupted world champion heavyweight grand master Troll Triggerer.🏆 I live rent-free in AffizzledGrampspoo's twisted head.🧌
1 · Reply
grampslol
grampslol Jul. 9 at 12:43 PM
poor $MNKD pumper @clan ... smh ... delusional cultist chumping the gullible about nadaburger furoscizzle and it's ability to get the afizzle company out of pennyworld... a sad 🤡 ... #pumperslie $PFE $BX $JNJ
0 · Reply
ghcolleen88
ghcolleen88 Jul. 9 at 12:39 PM
$MNKD
0 · Reply
clan
clan Jul. 9 at 12:36 PM
$MNKD $SPY $$QQQ 🚨 Only 11 trading days until a new, very needed, FDA product approval. ❤️ #furoscix #mannkind 🤑
0 · Reply
grampslol
grampslol Jul. 9 at 12:34 PM
$MNKD thursday morning script review afrezza dpi inhaled prandial insulin approved in 2014 ... weekly scripts ending 6/26/2026 new 333 refills 426 ... a pharmaceutical flop of epic proportions #afizzle #pennylandforever
0 · Reply
clan
clan Jul. 9 at 12:29 PM
$MNKD $JNJ $PFE $BX Mannkind's revenue growth projections for its upcoming FDA-approved Furoscix Ready•Flow Autoinjector have evolved from analysts' conservative projections originally derived last year during scPharma market valuations being made. #milestones #buyout #undervalued Up and to the right.
0 · Reply
Kuka
Kuka Jul. 9 at 12:20 PM
$MNKD LFG
0 · Reply
Joew22222
Joew22222 Jul. 9 at 12:19 PM
$MNKD
0 · Reply
pierrules
pierrules Jul. 9 at 11:34 AM
$MNKD 🌞
0 · Reply
grampslol
grampslol Jul. 9 at 10:45 AM
$MNKD Solidarity will triumph over the shorts ...
0 · Reply
grampslol
grampslol Jul. 9 at 10:43 AM
$MNKD poor @clan... 🤡
0 · Reply
clan
clan Jul. 9 at 9:48 AM
$UTHR Did somebody mention a bridge study for IPF and PPF? YUUUUGE! That'll be GREAT for all Mannkind ... and $MNKD #tyvasodpi 10% for the big guy. #technosphere
0 · Reply
clan
clan Jul. 9 at 9:42 AM
$MNKD As more and more revenue sources get added to analysts' long-range forecasts for Mannkind, MNKD will continue to rise up to catch their ever-increasing revised price targets. $27IN'27 🙄 $SPY 👀 $$QQQ 🤑 $BX ☝️
0 · Reply
JustAnotherAffizle
JustAnotherAffizle Jul. 9 at 7:58 AM
$MNKD It is quite telling you have not acknowledged and apologized for your grave error in misrepresenting my post. That tells me a lot about your character, or lack of it.
0 · Reply
grampslol
grampslol Jul. 9 at 4:38 AM
Look, it's poor @clan 👀 pennyland $MNKD pumperman clanscam deluding himself about $QQQ and hyping pdufa nadaburger 👀 to the gullible and $SPY ... a cultist 🤡 ... #afizzle #800millionauthorizedshares #dilutionsthesolution
0 · Reply
Pickin
Pickin Jul. 9 at 4:14 AM
$MNKD so half the days volume in the last few minutes and those huge buys have no effect on the price? Hmmm 🤔
1 · Reply
clan
clan Jul. 9 at 3:22 AM
$MNKD $SPY $QQQ PDUFA incoming. For the good of all Mannkind.
1 · Reply
Doctorgreenback
Doctorgreenback Jul. 9 at 12:43 AM
$MNKD feeling better about the stock Took years and admittedly, much pain. I’m expecting Afrezza to break 1000 weekly in about 6 weeks (I know). Expecting fda approval in 2. I’m expecting a decent q2 report. These big end of day blocks suggest a lot is happening behind the scenes as shorts exit and tutes acquire. If they are really in the 60-80% ownership range as some have speculated, we should be in for quite a ride.
0 · Reply